On June 24, 2022, Hexima Limited announced that based on its preliminary review, the results of its phase II clinical study of pezadeftide for the treatment of onychomycosis (HXP124-ONY-002) are inconclusive and will require further detailed investigation and evaluation. The results seen in this study do not appear to correlate with results observed in its prior phase I study (HXP124-ONY-001) and do not support moving directly into a phase III program. Hexima intends to conduct a detailed review of the complete clinical trial data set and study conduct and expects to report its findings when complete.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.013 AUD | 0.00% | 0.00% | -27.78% |
Mar. 22 | Hexima Secures R&D Tax Rebate for Fiscal Year 2023 | MT |
Mar. 19 | Hexima Changes Address | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-27.78% | 1.41M | |
+0.86% | 43.84B | |
+5.67% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+6.11% | 25.53B | |
-24.70% | 18.18B | |
-3.10% | 12.29B | |
+25.98% | 12.29B | |
+6.86% | 11.15B |
- Stock Market
- Equities
- HXL Stock
- News Hexima Limited
- Hexima Limited Announces Preliminary Results of Phase II Clinical Study of Pezadeftide